GCG and chronic kidney disease: Recent guidelines issued by American Diabetes Association recommend GLP1 agonists as second line treatment for diabetic patients with cardiovascular disease or SGLT2 inhibitors if there are established comorbidities like chronic kidney disease, heart failure, and others, whereas SU, DPP-4 inhibitors and TZDs are recommended as fourth line therapies after combination therapies and GLP-1 agonists.77GLP1 agonists are a new class of antidiabetic medication.